Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection-Reference-Cited by-同舟云学术

Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lanoix Jean-Philippe¹²^ORCID,Joseph Cédric¹²,Peltier François¹,Castelain Sandrine¹³,Andréjak Claire¹⁴

Affiliation:

1. AGIR EA 4294, University Center of Research and Health (CURS), Amiens, France

2. Department of Infectious Disease, University Hospital of Amiens-Picardie, Amiens, France

3. Department of Microbiology, University Hospital of Amiens-Picardie, Amiens, France

4. Department of Pneumology, University Hospital of Amiens-Picardie, Amiens, France

Abstract

Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of Mycobacterium avium . In an aerosol infection BALB/c mouse model using M. avium strain Chester, we treated 58 mice with four combinations of rifampin (RIF) at 10 mg/kg, CFZ at 25 mg/kg, and clarithromycin (CLR) and ethambutol (EMB) at 100 mg/kg.

Funder

Comité départemental de lutte contre les maladies respiratoires

Conseil Régional de Picardie

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02349-19

Reference19 articles.

1. Treatment ofMycobacterium aviumComplex Pulmonary Disease

2. Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice